In December 2005, Eli Lilly and Firm agreed to plead guilty and shell out $36 million in reference to the unlawful advertising of the drug.[264] Product sales representatives were being properly trained to advertise Evista for breast cancer and heart problems, to prompt or bait queries by Physic